三优生物成立于2015年，是一家国际领先的专注于创新生物药研发和服务的生物高科技企业。公司致力于打通药物研究与开发“端对端”完整的供应链，构建“差异化CRO、整合型CDO、协同型CPO、特色CRS”于一体的4C业务体系，实现“让天下没有难做的创新生物药”的使命。三优生物建立了20000余平方米、设施设备先进齐全的创新生物药一体化研发实验室。公司打造了居于行业领军水平的 “超万亿、一体化、智能化”三大创新药研发技术平台，及以超万亿噬菌体展示抗体库为代表的，涵盖原材料制备、分子发现、分子优化、体内外药效、生产用细胞株构建、上下游工艺开发、临床前研发及产业化开发等50多个核心创新技术子平台。公司持续推出“创新、卓越、可靠”（三优）的新技术、新产品、新服务和新场景，并和全球1000多家制药公司、药物研发机构、诊断试剂产品公司建立了友好的业务合作关系。 Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched
On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform").
As one of the nine trillion antibody discovery
platforms of Sanyou, the platform features a library capacity of up to 1.12E+12 CFU. For a single target, the platform can generate hundreds of lead antibodies
with diverse sequences, which can be further designed into bispecific
antibodies with good drug developability, providing a feasible solution for
obtaining bispecific antibodies with structures similar to the natural
monoclonal antibodies.
Bispecific antibodies are at the forefront of
antibody R&D field. Compared with monoclonal antibodies, bispecific
antibodies possess one additional antigen binding arm, which brings
stronger specificity and better targeting. As of March of 2023, 436 bispecific
antibody drug candidates have advanced to clinical trials worldwide, and 10
bispecific antibody drugs had been approved for marketing, with sales of more
than 5 billion USD.
The antibody library of the platform was
established in a rigorous way. To be specific, 2 common light chains were
selected through alignment and screening of 1800+ light chain sequences,
validation of 25 proof-of-concept libraries, and antibody characterization and
analysis of 12 light chains. The bispecific antibodies generated by this
platform exhibit good drug developability, and the heavy chains possess natural
antibody properties and high diversity. The platform employs the knob-into-hole
technology to ensure the correct pairing in the process of bispecific antibody formation
and eliminate the mismatch. These common light chain antibodies are suitable
for multiple application scenarios, such as bispecific antibody development,
dual-targeting or bi-paratopic ADC, and therapeutic or detection antibodies.Following the customer-oriented concept, the
platform provides two types of services, i.e., library screening and library
integration, making it not only suitable for the R&D service of individual
projects, but also for customers’ integration into their own platforms with the
exclusively customized common light chain libraries.It is believed that the launch of the platform will
provide customers with great assistance in overcoming the difficulties in the
R&D of bispecific antibody drugs, reducing the challenges in the
development of bispecific antibody drugs, and greatly accelerating the R&D
of bispecific antibodies.
About Sanyou Bio
Sanyou Biopharmaceuticals Co., Ltd. is
a world-leading high-tech biotechnology enterprise focusing on R&D and
services of innovative biological drugs. Sanyou is committed to bridge drug
R&D and all-life-cycle manufacture supply chain, and has built the 4C
business patterns that integrate "differentiated CRO, integrated CDO,
innovative CPO and characteristic CRS”, to accomplish the mission “to make it
easy to discover innovative biological drugs anywhere”.Sanyou has established an integrated
innovative biological drug R&D laboratory of twenty thousand square meters
with advanced facilities, and has built three industry-leading innovative
technology platforms featured by “super-trillion, integration, and
intelligence" , which are comprised of more than 50 sub-platforms with the
core innovative super-trillion phage display platform, and supported by
platforms of material preparation, antibody discovery, molecule optimization,
in vitro and in vivo efficacy, production cell line construction, upstream and
downstream process development, preclinical R&D, industrialization development,
etc.Sanyou’s proprietary platform and
technology are in continuous optimisation，we launch from time to time upgrades and new version of services and
technologies based on principles of innovation, outstanding and reliability.
The company has established friendly business collaboration with more than 1000
pharmaceutical companies, drug R&D institutions and diagnostics companies
worldwide.
